Novavax, Inc. (NVAX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Novavax third quarter 2025 financial results and operational highlights conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then the digit one on your touch-tone phone. To withdraw your question, repeat the steps of star and one. Please note, this event is being recorded, and I would now like to turn the conference over to Louis Sene, Vice President, Investor Relations. Please go ahead, sir. Good morning, and thank you all for joining us today to discuss our third quarter 2025 financial results and operational highlights. A press release announcing our results is available on our website at Novavax.com, and an audio archive of this conference call will be available on our website later today. Please turn to slide two. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including but not limited to statements related to Novavax's corporate strategy and operating plans, its strategic priorities, its partnerships, and expectations with respect to potential royalties, milestones, cost reimbursements, its expectations regarding manufacturing capacity, timing, production, and delivery for its COVID-19 vaccine, the development of Novavax's clinical and preclinical product candidates, the timing and results of our clinical trials, timing of regulatory filings and actions, its APA agreements and related negotiations, full year 2025 financial guidance and revenue framework, full-year 2026 revenue framework preview, and Novavax's future financial or...